Tuesday, December 21, 2004

FDA Update

Now the NYTimes reports that a study by the National Institutes of Health has found that people taking Aleve had a 50% greater rate of heart problems, and by extension, ALL Nsaids, including Advil and pharmaceutical-strength Naprosyn, seem likely to cause similar problems.
For some odd reason the article goes onto speculate that this news could benefit Pfizer, for whom the Celebrex mess looks less damning by comparison because "...similar pills may be just as hurtful to the heart..."
The FDA's response?
"'This illustrates the fundamental dynamic that all drugs have risks," said Dr. Steven Galson, acting director of the Food and Drug Administration's center for drug evaluation and research. "All should be taken carefully.'"
For instance, avoided if the FDA gives them the green light?

No comments: